Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)
Year: 2014
Type: article
Source: Blood
Authors: Ajay K. Gopal, Brad S. Kahl, Sven de Vos, Nina D. Wagner-Johnston, Stephen J. Schuster, Wojciech Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter Martin, Andreas Viardot, Kristie A. Blum, Andre Goy, Andrew Davies, Pier Luigi Zinzani, Martin H. Dreyling, Leanne M. Holes, Bess Sorensen, Wayne R. Godfrey, Gilles Andre Salles
Institutions: University of Washington, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of California, Los Angeles, Los Angeles Medical Center, Washington University in St. Louis, Abramson Cancer Center, University of Pennsylvania, Jagiellonian University, Sarah Cannon, Winship Cancer Institute, Weill Cornell Medicine, University Hospital Ulm, The Ohio State University, Hackensack University Medical Center, University of Southampton, University of Bologna, München Klinik, Gilead Sciences (United States), Hôpital Lyon Sud
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2175253063